NGENF - NervGen Pharma receives ethics approval to initiate early-stage NVG-291 trial

NervGen Pharma (NGENF) has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTP?") inhibitor.The study protocol was also previously reviewed by the U.S. FDA and is intended to support the progression of a clinical study in the U.S. and Australia.The company said it remains on track to dose the first human subjects in Australia in Q2 2021.

For further details see:

NervGen Pharma receives ethics approval to initiate early-stage NVG-291 trial